{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:15:29Z","timestamp":1781918129667,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median overall survival of the total cohort treated with GPT was 18.7\u00a0months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.040 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1\u00a0months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60\u00a0Gy equivalents at gross tumor volume than those at the pancreatic head (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6\u00a0months after GTP than those without anterior peripancreatic invasion (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-022-02001-w","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T08:04:49Z","timestamp":1644480289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuta","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Nanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungChul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Shazrina","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-8460","authenticated-orcid":false,"given":"Hirochika","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","volume":"31","author":"G Carioli","year":"2020","unstructured":"Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020;31:650\u20138.","journal-title":"Ann Oncol"},{"key":"2001_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2001_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008\u201320.","journal-title":"Lancet"},{"key":"2001_CR4","doi-asserted-by":"crossref","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson III AB, Cardin DB, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439\u201357.","DOI":"10.6004\/jnccn.2021.0017"},{"key":"2001_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310.","journal-title":"Lancet Oncol"},{"key":"2001_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5:285\u201394.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2001_CR7","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer Sr","year":"2011","unstructured":"Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105\u201312.","journal-title":"J Clin Oncol"},{"key":"2001_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315:1844\u201353.","journal-title":"JAMA"},{"key":"2001_CR9","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","volume":"27","author":"CA Iacobuzio-Donahue","year":"2009","unstructured":"Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806\u201313.","journal-title":"J Clin Oncol"},{"key":"2001_CR10","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/cam4.459","volume":"4","author":"RD Peixoto","year":"2015","unstructured":"Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4:1171\u20137.","journal-title":"Cancer Med"},{"key":"2001_CR11","doi-asserted-by":"crossref","unstructured":"Thompson RF, Mayekar SU, Zhai H, Both S, Apisarnthanarax S, Metz JM, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. Med Phys. 2014;41:10.081711.","DOI":"10.1118\/1.4887797"},{"key":"2001_CR12","first-page":"108","volume":"6","author":"TC Ling","year":"2015","unstructured":"Ling TC, Slater JM, Mifflin R, Nookala P, Grove R, Ly AM, et al. Evaluation of normal tissue exposure in patients receiving radiotherapy for pancreatic cancer based on RTOG 0848. J Gastrointest Oncol. 2015;6:108\u201314.","journal-title":"J Gastrointest Oncol"},{"key":"2001_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/cncr.22542","volume":"109","author":"C Greco","year":"2007","unstructured":"Greco C, Wolden S. Current status of radiotherapy with proton and light ion beams. Cancer. 2007;109:1227\u201338.","journal-title":"Cancer"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","volume":"103","author":"K Terashima","year":"2012","unstructured":"Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, et al. A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012;103:25\u201331.","journal-title":"Radiother Oncol"},{"key":"2001_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.14338\/IJPT.14-00006.1","volume":"1","author":"S Sachsman","year":"2014","unstructured":"Sachsman S, Nichols RC, Morris CG, Zaiden R, Johnson EA, Awad Z, et al. Proton therapy and concomitant capecitabine for non-metastatic unresectable pancreatic adenocarcinoma. Int J Part Ther. 2014;1:692\u2013701.","journal-title":"Int J Part Ther"},{"key":"2001_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","volume":"17","author":"K Maemura","year":"2017","unstructured":"Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, et al. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Pancreatology. 2017;17:833\u20138.","journal-title":"Pancreatology"},{"key":"2001_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.radonc.2018.08.026","volume":"129","author":"M Shinoto","year":"2018","unstructured":"Shinoto M, Terashima K, Suefuji H, Matsunobu A, Toyama S, Fukunishi K, et al. A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2018;129:333\u20139.","journal-title":"Radiother Oncol"},{"key":"2001_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","volume":"136","author":"Y Hiroshima","year":"2019","unstructured":"Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2019;136:37\u201343.","journal-title":"Radiother Oncol"},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.13131184","volume":"270","author":"MM Al-Hawary","year":"2014","unstructured":"Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014;270:248\u201360.","journal-title":"Radiology"},{"key":"2001_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0360-3016(02)02949-8","volume":"54","author":"K Kagawa","year":"2002","unstructured":"Kagawa K, Murakami M, Hishikawa Y, Abe M, Akagi T, Yanou T, et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. Int J Radiat Oncol Biol Phys. 2002;54:928\u201338.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2001_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00534-011-0400-y","volume":"19","author":"H Shinchi","year":"2012","unstructured":"Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;19:152\u20138.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2001_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2012.03.059","volume":"85","author":"M Ikeda","year":"2013","unstructured":"Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, et al. A multicenter Phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:163\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2001_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.dld.2014.06.006","volume":"46","author":"M Ducreux","year":"2014","unstructured":"Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, et al. Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. Dig Liver Dis. 2014;46:950\u20135.","journal-title":"Dig Liver Dis"},{"key":"2001_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13014-015-0564-8","volume":"10","author":"M Fiore","year":"2015","unstructured":"Fiore M, Trodella L, Valeri S, Borzomati D, Floreno B, Ippolito E, et al. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. Radiat Oncol. 2015;10:255.","journal-title":"Radiat Oncol"},{"key":"2001_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/bjc.2017.95","volume":"116","author":"CN Hurt","year":"2017","unstructured":"Hurt CN, Falk S, Crosby T, McDonald A, Ray R, Joseph G, et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer. 2017;116:1264\u201370.","journal-title":"Br J Cancer"},{"key":"2001_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","volume":"94","author":"S Krishnan","year":"2016","unstructured":"Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:755\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2001_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.radonc.2017.04.010","volume":"123","author":"SY Chung","year":"2017","unstructured":"Chung SY, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiat Oncol. 2017;123:438\u201345.","journal-title":"Radiat Oncol"},{"key":"2001_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/apc.2018.07.03","volume":"1","author":"SP Ng","year":"2018","unstructured":"Ng SP, Koay EJ. Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy. Ann Pancreat Cancer. 2018;1:22.","journal-title":"Ann Pancreat Cancer"},{"key":"2001_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ijrobp.2018.04.057","volume":"101","author":"S Kawashiro","year":"2018","unstructured":"Kawashiro S, Yamada S, Okamoto M, Ohno T, Nakano T, Shinoto M, et al. Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan carbon-ion radiation oncology study group (J-CROS) Study 1403 pancreas. Int J Radiat Oncol Biol Phys. 2018;101:1212\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2001_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13014-020-01731-z","volume":"16","author":"D Lee","year":"2021","unstructured":"Lee D, Komatsu S, Terashima K, Toyama H, Matsuo Y, Takahashi D, et al. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. Radiat Oncol. 2021;16:3.","journal-title":"Radiat Oncol"},{"key":"2001_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","volume":"14","author":"S Satoi","year":"2016","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S, et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 2016;14:14.","journal-title":"World J Surg Oncol"},{"key":"2001_CR32","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ejso.2019.06.004","volume":"45","author":"M Suker","year":"2019","unstructured":"Suker M, Koerkamp BG, Coene PP, van der Harst E, Bonsing BA, Vahrmeijer AL, et al. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. Eur J Surg Oncol. 2019;45:1906\u201311.","journal-title":"Eur J Surg Oncol"},{"key":"2001_CR33","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","volume":"81","author":"A Mahadevan","year":"2011","unstructured":"Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011;81:e615\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2001_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00280-012-1918-7","volume":"70","author":"JS Kim","year":"2012","unstructured":"Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, et al. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2012;70:381\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2001_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","volume":"14","author":"S Mukherjee","year":"2013","unstructured":"Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317\u201326.","journal-title":"Lancet Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02001-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T08:23:30Z","timestamp":1644481410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02001-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02001-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1065586\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Hyogo Ion Beam Medical Center and conducted according to the ethical standards stated in the 1964 Declaration of Helsinki and its later amendments; the need for informed consent was waived owing to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}